ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Impact of age, BMI, and renal function adjustment on interpretation of serum NfL and GFAP in multiple sclerosis progression: a scoping review.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite achieving NEDA‑3, a substantial proportion of patients with multiple sclerosis (MS) accumulate disability through progression independent of relapse activity (PIRA). This scoping review evaluates serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in relation to disease activity and progression, with particular focus on the effects of age, BMI, and renal function on biomarker interpretation.
methodsThe review followed PRISMA‑ScR guidelines (PubMed, Scopus, Web of Science, January 2016 - February 2026). Longitudinal studies (≥ 12 months) with multivariable adjustment were prioritised. Of 467 screened records, 367 were excluded; 100 full‑text articles were assessed. Of these, 36 were excluded. Sixty‑four publications were included; 34 original analytical studies formed the basis of the structured synthesis.
resultssNfL was consistently associated with acute inflammatory activity, whereas associations with progression were less consistent after adjustment for age and other covariates. sGFAP showed stronger associations with PIRA and disability progression in several longitudinal studies, although findings were heterogeneous. PIRA definitions and follow-up durations varied substantially, limiting direct comparability. Evidence regarding renal-function adjustment was limited and heterogeneous: adjustment attenuated the association between sGFAP and progression in one study, whereas associations remained evident in other studies accounting for renal function.
conclusionsAge, BMI, and renal function should be considered when interpreting circulating NfL and GFAP, particularly in studies of progression. The available evidence does not support universal biomarker cut-offs or uniform interpretation of PIRA-associated concentrations. Prospective studies with harmonised PIRA definitions, sufficiently long follow-up, and consistent confounder adjustment are needed.
Indexed as
Identifiers
42753010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.